贝瑞基因
(000710)
| 流通市值：33.94亿 | | | 总市值：36.41亿 |
| 流通股本：3.30亿 | | | 总股本：3.54亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 210,215,582.68 | 929,818,022.06 | 685,656,794.86 | 447,434,341.07 |
| 营业收入 | 210,215,582.68 | 929,818,022.06 | 685,656,794.86 | 447,434,341.07 |
| 二、营业总成本 | 217,562,649.71 | 1,009,161,258.53 | 713,217,299.16 | 456,188,384.03 |
| 营业成本 | 101,989,226.46 | 528,602,652.28 | 358,237,030.94 | 225,830,709.82 |
| 税金及附加 | 483,749.8 | 5,506,633.49 | 3,560,164.11 | 2,366,866.24 |
| 销售费用 | 50,961,801.16 | 206,473,928.91 | 156,278,837.86 | 100,519,226.84 |
| 管理费用 | 38,992,651.17 | 157,752,381.05 | 111,508,352.12 | 71,666,893.4 |
| 研发费用 | 24,412,392.8 | 104,363,779.56 | 78,716,866.22 | 52,519,317.48 |
| 财务费用 | 722,828.32 | 6,461,883.24 | 4,916,047.91 | 3,285,370.25 |
| 其中:利息费用 | 1,949,508.01 | 9,979,243.93 | 8,055,393 | 5,513,610 |
| 其中:利息收入 | -405,425.98 | 3,196,609.04 | -3,648,364.94 | 2,557,480.82 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -2,841,154.08 | 2,203,689.24 | 2,203,689.24 |
| 加:投资收益 | -924,712.99 | -3,537,842.81 | 4,650,790.35 | 3,257,567.49 |
| 资产处置收益 | -842,035.43 | 4,998,568.37 | -569,132.28 | -11,541.91 |
| 资产减值损失(新) | - | 674,124.35 | - | - |
| 信用减值损失(新) | -10,320,279.5 | -108,982,571.91 | -21,703,535.22 | -15,756,033.26 |
| 其他收益 | 1,736,944.19 | 1,696,521.51 | 854,181.34 | 578,844.32 |
| 四、营业利润 | -17,697,150.76 | -187,335,591.04 | -42,124,510.87 | -18,481,517.08 |
| 加:营业外收入 | 158,701.44 | 4,005,221.05 | 177,133.48 | 6,439.78 |
| 减:营业外支出 | 44,366.84 | 6,225,796.07 | 1,338,475.25 | 1,200,420.21 |
| 五、利润总额 | -17,582,816.16 | -189,556,166.06 | -43,285,852.64 | -19,675,497.51 |
| 减:所得税费用 | 1,486,615.21 | 6,737,971.96 | 7,136,143.7 | 5,734,665.27 |
| 六、净利润 | -19,069,431.37 | -196,294,138.02 | -50,421,996.34 | -25,410,162.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -19,069,431.37 | -196,294,138.02 | -50,421,996.34 | -25,410,162.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -19,738,153.1 | -196,838,894.41 | -52,563,718.07 | -27,242,543.15 |
| 少数股东损益 | 668,721.73 | 544,756.39 | 2,141,721.73 | 1,832,380.37 |
| 扣除非经常损益后的净利润 | -19,707,266.42 | -206,498,039.43 | -53,791,445.01 | -28,589,541.41 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.06 | -0.56 | -0.15 | -0.08 |
| (二)稀释每股收益 | -0.06 | -0.56 | -0.15 | -0.08 |
| 八、其他综合收益 | -4,233,147.77 | -5,649,446.76 | -10,490,907.17 | -3,950,510.27 |
| 归属于母公司股东的其他综合收益 | -3,481,034.08 | -4,691,843.02 | -2,317,678.96 | -3,294,200.76 |
| 九、综合收益总额 | -23,302,579.14 | -201,943,584.78 | -60,912,903.51 | -29,360,673.05 |
| 归属于母公司股东的综合收益总额 | -23,219,187.18 | -201,530,737.43 | -54,881,397.03 | -30,536,743.91 |
| 归属于少数股东的综合收益总额 | -83,391.96 | -412,847.35 | -6,031,506.48 | 1,176,070.86 |
| 公告日期 | 2026-04-30 | 2026-04-29 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |